The Clinical Utility of Biomarkers in the Management of Pancreatic Adenocarcinoma

Seminars in Radiation Oncology

Volumn 24, Issue 2, 2014, Pages 67-76

  Jazieh, Khalid A ^a,b   Foote, Michael B ^a,b   Diaz, Luis A ^a,b  

^a Ludwig Center for Cancer Genetics and Therapeutics   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; CA 19-9 ANTIGEN; MEMBRANE PROTEIN; OSTEONECTIN; PALB2 PROTEIN; SMAD4 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; GENETIC MARKER;

CANCER MORTALITY; CANCER PROGNOSIS; CANCER RESEARCH; CANCER STEM CELL; CANCER SURVIVAL; DISEASE COURSE; FAMILY HISTORY; FANCONI ANEMIA; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS ADENOCARCINOMA; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; UNITED STATES; ADENOCARCINOMA; ANIMAL; GENETIC MARKER; GENETIC PREDISPOSITION; PANCREATIC NEOPLASMS; PROGNOSIS;

ADENOCARCINOMA; ANIMALS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84895858576     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.11.007     Document Type: Review

References (137)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
3. Li D., Xie K., Wolff R., et al. Pancreatic cancer. Lancet 2004, 363:1049-1057.
4. Tseng J.F., Raut C.P., Lee J.E., et al. Pancreaticoduodenectomy with vascular resection: Margin status and survival duration. J Gastrointest Surg 2004, 8:935-949. [discussion 949-50].
5. De Jesus-Acosta A., Oliver G.R., Blackford A., et al. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2012, 69:415-424.
6. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825.
7. Group B.D.W. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
8. Riley R.D., Sauerbrei W., Altman D.G. Prognostic markers in cancer: The evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 2009, 100:1219-1229.
9. Galea M.H., Blamey R.W., Elston C.E., et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992, 22:207-219.
10. Oldenhuis C.N., Oosting S.F., Gietema J.A., et al. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008, 44:946-953.
11. Smith I., Procter M., Gelber R.D., et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2007, 369:29-36.
12. Fong Z.V., Winter J.M. Biomarkers in pancreatic cancer: Diagnostic, prognostic, and predictive. Cancer J 2012, 18:530-538.
13. Duffy M.J., Sturgeon C., Lamerz R., et al. Tumor markers in pancreatic cancer: A European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010, 21:441-447.
14. Magnani J.L., Steplewski Z., Koprowski H., et al. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 1983, 43:5489-5492.
15. Glenn J., Steinberg W.M., Kurtzman S.H., et al. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988, 6:462-468.
16. Koprowski H., Steplewski Z., Mitchell K., et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979, 5:957-971.
17. Narimatsu H., Iwasaki H., Nakayama F., et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998, 58:512-518.
18. Tempero M.A., Uchida E., Takasaki H., et al. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987, 47:5501-5503.
19. Locker G.Y., Hamilton S., Harris J., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006, 24:5313-5327.
20. Bedi M.M., Gandhi M.D., Jacob G., et al. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: Is there any benefit?. Indian J Gastroenterol 2009, 28:24-27.
21. Galli C., Basso D., Plebani M. CA 19-9: Handle with care. Clin Chem Lab Med 2013, 1-15.
22. Decker G.A., Batheja M.J., Collins J.M., et al. Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (N Y) 2010, 6:246-254.
23. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990, 85:350-355.
24. Kim J.E., Lee K.T., Lee J.K., et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004, 19:182-186.
25. Barton J.G., Bois J.P., Sarr M.G., et al. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg 2009, 13:2050-2058.
26. Wentz S.C., Zhao Z.G., Shyr Y., et al. Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma. World J Gastrointest Oncol 2012, 4:207-215.
27. Kim Y.C., Kim H.J., Park J.H., et al. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?. J Gastroenterol Hepatol 2009, 24:1869-1875.
28. Konigsrainer I., Zieker D., Symons S., et al. Do patient- and tumor-related factors predict the peritoneal spread of pancreatic adenocarcinoma?. Surg Today 2013, [Epub ahead of print].
29. Kang C.M., Kim J.Y., Choi G.H., et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 2007, 140:31-35.
30. Marrelli D., Caruso S., Pedrazzani C., et al. CA19-9 serum levels in obstructive jaundice: Clinical value in benign and malignant conditions. Am J Surg 2009, 198:333-339.
31. Berger A.C., Garcia M., Hoffman J.P., et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. J Clin Oncol 2008, 26:5918-5922.
32. Kondo N., Murakami Y., Uemura K., et al. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2010, 17:2321-2329.
33. Kinsella T.J., Seo Y., Willis J., et al. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol 2008, 31:446-453.
34. Ballehaninna U.K., Chamberlain R.S. Serum CA 19-9 as a biomarker for pancreatic cancer-A comprehensive review. Indian J Surg Oncol 2011, 2:88-100.
35. Hata S., Sakamoto Y., Yamamoto Y., et al. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2012, 19:636-641.
36. Hammad N., Heilbrun L.K., Philip P.A., et al. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. Asia Pac J Clin Oncol 2010, 6:98-105.
37. Haas M., Heinemann V., Kullmann F., et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: Results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol 2013, 139:681-689.
38. Rudra S., Narang A.K., Pawlik T.M., et al. Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Pract Radiat Oncol 2012, 2:77-85.
39. Humphris J.L., Chang D.K., Johns A.L., et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 2012, 23:1713-1722.
40. Reni M., Cereda S., Balzano G., et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009, 115:2630-2639.
41. Halm U., Schumann T., Schiefke I., et al. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000, 82:1013-1016.
42. Wong D., Ko A.H., Hwang J., et al. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas 2008, 37:269-274.
43. Waraya M., Yamashita K., Katagiri H., et al. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol 2009, 16:1231-1240.
44. Katz M.H., Varadhachary G.R., Fleming J.B., et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 2010, 17:1794-1801.
45. Singh P., Wig J.D., Srinivasan R. The Smad family and its role in pancreatic cancer. Indian J Cancer 2011, 48:351-360.
46. van Heek T., Rader A.E., Offerhaus G.J., et al. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: A molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol 2002, 117:755-765.
47. Hahn S.A., Schutte M., Hoque A.T., et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271:350-353.
48. Schutte M., Hruban R.H., Hedrick L., et al. DPC4 gene in various tumor types. Cancer Res 1996, 56:2527-2530.
49. Wilentz R.E., Su G.H., Dai J.L., et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation. Am J Pathol 2000, 156:37-43.
50. Yachida S., White C.M., Naito Y., et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res 2012, 18:6339-6347.
51. Wilentz R.E., Iacobuzio-Donahue C.A., Argani P., et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000, 60:2002-2006.
52. Yonezawa S., Higashi M., Yamada N., et al. Precursor lesions of pancreatic cancer. Gut Liver 2008, 2:137-154.
53. McCarthy D.M., Brat D.J., Wilentz R.E., et al. Pancreatic intraepithelial neoplasia and infiltrating adenocarcinoma: Analysis of progression and recurrence by DPC4 immunohistochemical labeling. Hum Pathol 2001, 32:638-642.
54. Chow J.Y., Ban M., Wu H.L., et al. TGF-beta downregulates PTEN via activation of NF-kappaB in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol 2010, 298:G275-G282.
55. Levy L., Hill C.S. Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 2005, 25:8108-8125.
56. Jiang H., He C., Geng S., et al. RhoT1 and Smad4 are correlated with lymph node metastasis and overall survival in pancreatic cancer. PLoS One 2012, 7:e42234.
57. Oshima M., Okano K., Muraki S., et al. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg 2013, 336-346.
58. Iacobuzio-Donahue C.A., Fu B., Yachida S., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009, 27:1806-1813.
59. Blackford A., Serrano O.K., Wolfgang C.L., et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009, 15:4674-4679.
60. Singh P., Srinivasan R., Wig J.D. SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2012, 41:541-546.
61. Wang H., Han H., Von Hoff D.D. Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Cancer Res 2006, 66:9722-9730.
62. Wang H., Stephens B., Von Hoff D.D., et al. Identification and characterization of a novel anticancer agent with selectivity against deleted in pancreatic cancer locus 4 (DPC4)-deficient pancreatic and colon cancer cells. Pancreas 2009, 38:551-557.
63. Reya T., Morrison S.J., Clarke M.F., et al. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
64. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
65. Al-Hajj M., Wicha M.S., Benito-Hernandez A., et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
66. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
67. Galli R., Binda E., Orfanelli U., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004, 64:7011-7021.
68. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
69. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
70. Todaro M., Alea M.P., Di Stefano A.B., et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
71. Izumiya M., Kabashima A., Higuchi H., et al. Chemoresistance is associated with cancer stem cell-like properties and epithelial-to-mesenchymal transition in pancreatic cancer cells. Anticancer Res 2012, 32:3847-3853.
72. Li C., Heidt D.G., Dalerba P., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
73. Lee C.J., Dosch J., Simeone D.M. Pancreatic cancer stem cells. J Clin Oncol 2008, 26:2806-2812.
74. Hermann P.C., Huber S.L., Herrler T., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
75. Li C., Wu J.J., Hynes M., et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011, 141:2218-2227. ([e5]).
76. Rasheed Z.A., Yang J., Wang Q., et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010, 102:340-351.
77. Kawamoto M., Ishiwata T., Cho K., et al. Nestin expression correlates with nerve and retroperitoneal tissue invasion in pancreatic cancer. Hum Pathol 2009, 40:189-198.
78. Cheng K.H., Su H.T., Weng C.C., et al. Stem cell marker Nestin is critical for TGF beta1-mediated tumor progression in pancreatic cancer. Mol Cancer Res 2013.
79. Matsuda Y., Naito Z., Kawahara K., et al. Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis. Cancer Biol Ther 2011, 11:512-523.
80. Kim H.S., Yoo S.Y., Kim K.T., et al. Expression of the stem cell markers CD133 and Nestin in pancreatic ductal adenocarcinoma and clinical relevance. Int J Clin Exp Pathol 2012, 5:754-761.
81. Wang D., Zhu H., Zhu Y., et al. CD133(+)/CD44(+)/Oct4(+)/Nestin(+) stem-like cells isolated from Panc-1 cell line may contribute to multi-resistance and metastasis of pancreatic cancer. Acta Histochem 2013, 115:349-356.
82. Lynch H.T., Fitzsimmons M.L., Smyrk T.C., et al. Familial pancreatic cancer: Clinicopathologic study of 18 nuclear families. Am J Gastroenterol 1990, 85:54-60.
83. Hruban R.H., Petersen G.M., Ha P.K., et al. Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin N Am 1998, 7:1-23.
84. Hruban R.H., Canto M.I., Goggins M., et al. Update on familial pancreatic cancer. Adv Surg 2010, 44:293-311.
85. Del Chiaro M., Zerbi A., Falconi M., et al. Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. Pancreatology 2007, 7:459-469.
86. Offit K., Levran O., Mullaney B., et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003, 95:1548-1551.
87. Gallmeier E., Hucl T., Calhoun E.S., et al. Gene-specific selection against experimental Fanconi anemia gene inactivation in human cancer. Cancer Biol Ther 2007, 6:654-660.
88. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007, 8:735-748.
89. Berwick M., Satagopan J.M., Ben-Porat L., et al. Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Res 2007, 67:9591-9596.
90. Wagner J.E., Tolar J., Levran O., et al. Germline mutations in BRCA2: Shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood 2004, 103:3226-3229.
91. Barber L.J., Sandhu S., Chen L., et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol 2013, 229:422-429.
92. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999, 91:1310-1316. The Breast Cancer Linkage Consortium.
93. Goggins M., Schutte M., Lu J., et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996, 56:5360-5364.
94. Murphy K.M., Brune K.A., Griffin C., et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Res 2002, 62:3789-3793.
95. Lucas A.L., Shakya R., Lipsyc M.D., et al. High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res 2013, 3396-3403.
96. van der Heijden M.S., Yeo C.J., Hruban R.H., et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003, 63:2585-2588.
97. Jones S., Hruban R.H., Kamiyama M., et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324:217.
98. Tischkowitz M.D., Sabbaghian N., Hamel N., et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 2009, 137:1183-1186.
99. Slater E.P., Langer P., Niemczyk E., et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet 2010, 78:490-494.
100. Uziel O., Reshef H., Ravid A., et al. Oxidative stress causes telomere damage in Fanconi anaemia cells - a possible predisposition for malignant transformation. Br J Haematol 2008, 142:82-93.
101. van der Heijden M.S., Brody J.R., Gallmeier E., et al. Functional defects in the Fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 2004, 165:651-657.
102. van der Heijden M.S., Brody J.R., Dezentje D.A., et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005, 11:7508-7515.
103. Lowery M.A., Kelsen D.P., Stadler Z.K., et al. An emerging entity: Pancreatic adenocarcinoma associated with a known BRCA mutation: Clinical descriptors, treatment implications, and future directions. Oncologist 2011, 16:1397-1402.
104. Sonnenblick A., Kadouri L., Appelbaum L., et al. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther 2011, 12:165-168.
105. James E., Waldron-Lynch M.G., Saif M.W. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: A case report and review of literature. Anticancer Drugs 2009, 20:634-638.
106. Villarroel M.C., Rajeshkumar N.V., Garrido-Laguna I., et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011, 10:3-8.
107. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005, 434:913-917.
108. McCabe N., Lord C.J., Tutt A.N., et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: An issue of potency. Cancer Biol Ther 2005, 4:934-936.
109. Burkhart R.A., Peng Y., Norris Z.A., et al. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. Mol Cancer Res 2013, 901-911.
110. Fogelman D.R., Wolff R.A., Kopetz S., et al. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res 2011, 31:1417-1420.
111. Lord C.J., Ashworth A. The DNA damage response and cancer therapy. Nature 2012, 481:287-294.
112. Harinck F., Kluijt I., van Mil S.E., et al. Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. Eur J Hum Genet 2012, 20:577-579.
113. Neuzillet C., Tijeras-Raballand A., Cros J., et al. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev 2013.
114. Raines E.W., Lane T.F., Iruela-Arispe M.L., et al. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci U S A 1992, 89:1281-1285.
115. Sato N., Fukushima N., Maehara N., et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003, 22:5021-5030.
116. Puolakkainen P.A., Brekken R.A., Muneer S., et al. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2004, 2:215-224.
117. Yardley D.A. nab(R)-paclitaxel mechanisms of action and delivery. J Control Release 2013, 365-372.
118. Garber K. Stromal depletion goes on trial in pancreatic cancer. J Natl Cancer Inst 2010, 102:448-450.
119. Von Hoff D.D., Ramanathan R.K., Borad M.J., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol 2011, 29:4548-4554.
120. Hosein P.J., de Lima Lopes G., Pastorini V.H., et al. A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 2013, 36:151-156.
121. Mitsunaga S., Hasebe T., Iwasaki M., et al. Important prognostic histological parameters for patients with invasive ductal carcinoma of the pancreas. Cancer Sci 2005, 96:858-865.
122. Adsay N.V., Basturk O., Bonnett M., et al. A proposal for a new and more practical grading scheme for pancreatic ductal adenocarcinoma. Am J Surg Pathol 2005, 29:724-733.
123. Cameron J.L., Crist D.W., Sitzmann J.V., et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991, 161:120-124. [discussion 124-5].
124. Iodice S., Gandini S., Maisonneuve P., et al. Tobacco and the risk of pancreatic cancer: A review and meta-analysis. Langenbecks Arch Surg 2008, 393:535-545.
125. Bosetti C., Lucenteforte E., Silverman D.T., et al. Cigarette smoking and pancreatic cancer: An analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol 2012, 23:1880-1888.
126. Blackford A., Parmigiani G., Kensler T.W., et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res 2009, 69:3681-3688.
127. Lin Y., Yagyu K., Ueda J., et al. Active and passive smoking and risk of death from pancreatic cancer: Findings from the Japan Collaborative Cohort Study. Pancreatology 2013, 13:279-284.
128. Momi N., Ponnusamy M.P., Kaur S., et al. Nicotine/cigarette smoke promotes metastasis of pancreatic cancer through alpha7nAChR-mediated MUC4 upregulation. Oncogene 2013, 32:1384-1395.
129. Dandona M., Linehan D., Hawkins W., et al. Influence of obesity and other risk factors on survival outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer. Pancreas 2011, 40:931-937.
130. Dumitrascu T., Barbu S.T., Purnichescu-Purtan R., et al. Risk factors for surgical complications after central pancreatectomy. Hepatogastroenterology 2012, 59:592-598.
131. Adair T., Hoy D., Dettrick Z., et al. Tobacco consumption and pancreatic cancer mortality: What can we conclude from historical data in Australia?. Eur J Public Health 2012, 22:243-247.
132. Wu J., Matthaei H., Maitra A., et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011, 3:92ra66.
133. Furukawa T., Kuboki Y., Tanji E., et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011, 1:161.
134. Koo B.K., Spit M., Jordens I., et al. Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 2012, 488:665-669.
135. Sugiura T., Yamaguchi A., Miyamoto K. A cancer-associated RING finger protein, RNF43, is a ubiquitin ligase that interacts with a nuclear protein, HAP95. Exp Cell Res 2008, 314:1519-1528.
136. Wang K., Li N., Yeung C.H., et al. Oncogenic Wnt/beta-catenin signalling pathways in the cancer-resistant epididymis have implications for cancer research. Mol Hum Reprod 2013, 19:57-71.
137. Jiang X., Hao H.X., Growney J.D., et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 2013, 110:12649-12654.